Sponsor pipeline

Dana-Farber Cancer Institute clinical trial pipeline

Get alerts when Dana-Farber Cancer Institute's trials change

235 active trials 103 recruiting 2 Phase 3 41 disease areas 30 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days

2026-10-01
Primary completion pushed: 2026-09-01 → 2027-07-01
Completion pushed: 2027-08-07 → 2027-12-30
NCT06565052 The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative…
2026-09-23
Primary completion pushed: 2026-08-31 → 2028-08-31
Enrollment closed, study ongoing
Completion pushed: 2026-10-31 → 2028-10-31
NCT06807294 Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy…
2026-09-23
Primary completion pushed: 2026-09-30 → 2028-09-30
Completion pushed: 2026-09-30 → 2028-09-30
NCT05121558 The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral…
2026-09-22
Primary completion pushed: 2026-06 → 2026-12
Completion pushed: 2026-10 → 2026-12
NCT02520713 The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
2026-09-03
Primary completion pushed: 2026-09-01 → 2027-05-01
NCT06488378 Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2… · Phase 1
2026-09-17
Primary completion pushed: 2026-09-30 → 2027-01-15
Completion pushed: 2028-03-30 → 2028-06-15
NCT06609473 Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF)…
2026-09-11
Primary completion pushed: 2026-08-28 → 2027-08-28
Completion pushed: 2027-02-28 → 2028-02-28
NCT06040125 Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With…
2026-09-04
Primary completion pushed: 2026-01-29 → 2026-06-09
NCT04724499 Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer…
2026-09-25
Primary endpoint(s) modified
Results posted: 2026-09-24
NCT04584255 Niraparib + Dostarlimab In BRCA Mutated Breast Cancer · Phase 2
2026-09-23
Primary endpoint(s) modified
Results posted: 2026-09-22
NCT02537613 A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic… · Phase 1
2026-09-11
Enrollment reduced: 257 → 147 participants
NCT04674267 Resilience and Equity in Aging, Cancer, and Health (REACH)
2026-10-01
Trial completed
Study completion confirmed: August 2025 (last estimated December 2026)
NCT03749421 Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women…
2026-09-26
Recruitment opened
NCT07729150 Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes
2026-09-10
Trial completed
NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer · Phase 2
2026-09-30
Primary completion pushed: 2026-08-31 → 2026-10-31
Completion pushed: 2026-09-15 → 2028-12
NCT04720209 Taking AIM at Breast Cancer
2026-09-17
Recruitment opened
NCT07232043 ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for…
2026-09-17
Completion pushed: 2026-08-01 → 2027-08-01
NCT04938232 Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL · Phase 2
2026-09-12
Completion pushed: 2026-06-30 → 2026-12-30
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE) · Phase 2
2026-09-05
Completion pushed: 2026-06-30 → 2027-06-30
NCT02981940 A Study of Abemaciclib in Recurrent Glioblastoma · Phase 2

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-09-29 NCT07847957 Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Phase 1/2 Not Yet Recruiting
2026-09-21 NCT07832227 Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Phase 2 Not Yet Recruiting
2026-09-17 NCT07825051 Healing Gardens: Leveraging Serious Games to Deliver Accessible Pain-CBT and… Not Yet Recruiting
2026-09-15 NCT07821177 Bladder Preservation or Cystectomy for MIBC Early Phase 1 Active, Not Recruiting

Active trials by phase

Early Phase 1
5
Phase 1
34
Phase 1/2
13
Phase 2
70
Phase 3
2
Phase 4
1
Not charted: 110 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 235

NCT IDTitleConditionStatusUpdated
Phase 4
NCT07426484 Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cutaneous Squamous Cell Carcinoma Recruiting 2026-08-11
Phase 3
NCT07624513 D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation &… Multiple Myeloma Not Yet Recruiting 2026-09-08
NCT03020030 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Acute Lymphoblastic Leukemia, Pediatric Active, Not Recruiting 2026-07-16
Phase 2
NCT06366347 ALPINE: Maintenance Letrozole/Abemaciclib Endometrial Cancer Recruiting 2026-09-16
NCT06940180 Toripalimab With Chemotherapy for Sinus Cancer Sinonasal Cancer Recruiting 2026-08-31
NCT04893109 ATEMPT 2.0: Adjuvant T-DM1 vs TH Breast Cancer Recruiting 2026-08-19
NCT06239220 PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC Head and Neck Cancer Recruiting 2026-08-18
NCT07735624 RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer Early Rectal Cancer Recruiting 2026-08-18
NCT07227584 ALL Backbone in AYAs Acute Lymphoblastic Leukemia Recruiting 2026-08-17
NCT06439693 The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic… Breast Cancer Female Recruiting 2026-08-06
NCT05765500 RecoverPC: Relugolix vs GnRH Agonist in Quality of Life Prostate Cancer Recruiting 2026-07-30
NCT05726370 Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Head and Neck Squamous Cell Carcinoma Recruiting 2026-06-23
NCT03675893 RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer Endometrial Cancer Recruiting 2026-06-22
NCT04986579 Scalp Cooling in MBC Metastatic Breast Cancer Recruiting 2026-06-18
NCT05922761 BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Bronchiolitis Obliterans Syndrome Recruiting 2026-06-10
NCT07434843 PH 2 Pemigatinib in SDH-deficient GIST SDH Gene Mutation Recruiting 2026-05-22
NCT07467772 Ph 2 Elacestrant in ER Positive Uterine Sarcomas Uterine Sarcoma Recruiting 2026-05-22
NCT04434040 Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Breast Cancer Recruiting 2026-05-04
NCT03310879 Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations… Cancer Recruiting 2026-04-29
NCT04468061 Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Breast Cancer Recruiting 2026-04-29
NCT07123649 Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors… Breast Cancer Recruiting 2026-04-22
NCT04620187 Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Salivary Gland Cancer Recruiting 2026-04-13
NCT07465276 Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting 2026-03-27
NCT07397611 Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Renal Cell Carcinoma Recruiting 2026-03-20
NCT05168930 Zanubrutinib and Venetoclax in CLL (ZANU-VEN) Chronic Lymphocytic Leukemia (CLL) Recruiting 2025-12-05
See all 235 active Dana-Farber Cancer Institute trials with filters →

Disease areas by active trials, top 10 of 41

Breast Cancer (47) · Leukemia (34) · Lung Cancer (16) · Head & Neck Cancer (13) · Prostate Cancer (12) · Chronic Lymphocytic Leukemia (CLL) (11) · Multiple Myeloma (11) · Acute Myeloid Leukemia (AML) (10) · Endometrial Cancer (10) · Ovarian Cancer (10)

Get alerts when Dana-Farber Cancer Institute's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free